Skip to main content
logo
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,124.21
+0.30 (0.03%)
At close: Sep 9, 2026, 4:00 PM EDT
1,131.00
+6.79 (0.60%)
Pre-market: Sep 10, 2026, 5:46 AM EDT

Eli Lilly Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Cardiometabolic
61.78B54.77B48.22B42.84B37.06B33.24B29.52B26.16B
Cardiometabolic Growth
66.69%64.80%63.35%63.74%57.90%58.49%50.10%46.17%
Oncology
9.85B9.70B9.38B9.32B9.14B8.89B8.75B8.08B
Oncology Growth
7.74%9.07%7.12%15.29%20.33%24.99%31.45%25.83%
Immunology
5.52B5.36B5.25B5.00B4.82B4.65B4.39B4.21B
Immunology Growth
14.59%15.39%19.44%18.79%20.28%20.59%15.68%15.98%
Neuroscience
1.59B1.50B1.39B1.32B1.36B1.36B1.47B1.44B
Neuroscience Growth
16.52%10.65%-5.60%-8.19%-52.40%-53.34%-48.81%-50.26%
Other
920.60M917.10M943.00M942.20M867.80M873.90M902.90M968.50M
Other Growth
6.08%4.94%4.44%-2.72%-11.61%-19.74%-19.54%-20.74%

Revenue by Geography

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016
United States
53.06B49.99B48.36B44.23B
United States Growth
9.74%13.04%25.25%26.22%
Europe
14.36B12.82B11.56B10.91B9.04B7.87B6.92B5.81B--
Europe Growth
58.81%62.85%67.01%87.76%33.91%20.61%12.08%-1.71%--
Rest of World
9.53B7.83B6.06B4.93B4.35B4.38B4.27B3.95B--
Rest of World Growth
118.92%78.98%41.81%24.78%20.08%38.20%44.97%30.64%--
China
2.67B2.19B1.95B1.91B1.81B1.74B1.66B1.61B--
China Growth
47.75%26.40%17.52%18.52%17.31%12.43%7.83%6.28%--
Japan
2.41B2.30B2.13B2.04B1.91B1.85B1.81B1.69B--
Japan Growth
26.00%24.19%17.48%20.18%15.38%12.34%8.50%4.06%--

Operating Expense Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
14.60B14.11B13.34B12.56B11.83B11.20B10.99B10.53B
Research and Development Growth
23.42%25.99%21.35%19.25%15.88%13.71%18.01%20.40%
Marketing, Selling, and Administrative
12.24B11.56B11.09B10.39B9.75B9.11B8.59B8.09B
Marketing, Selling, and Administrative Growth
25.55%26.88%29.09%28.33%24.98%19.78%16.08%13.65%
Acquired In-Process Research and Development
4.54B1.92B2.91B2.57B4.74B4.74B3.28B3.71B
Acquired In-Process Research and Development Growth
-4.15%-59.46%-11.29%-30.79%22.75%24.61%-13.67%8.68%
Impairment, Restructuring, and Other
1.43B728.00M484.00M743.90M460.60M895.60M860.60M523.37M
Impairment, Restructuring, and Other Growth
210.68%-18.71%-43.76%42.14%4.26%13,128.95%12,611.96%1,273.67%